Rebamipide in Patients With Active Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Although the aetiology of RA remains to be fully elucidated, interleukin (IL)-17 are believed
to play a critical role in the pathogenesis of RA. Rebamipide is an antiulcer drug that
protects gastric epithelial cells,improves gastric defense mechanisms by increasing gastric
mucus. Rebamipide inhibited interleukin (IL)-17, also it inhibits IL-1β-induced RASF
proliferation.